KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Gsk (GSK) Non Operating Income (2016 - 2026)

Gsk has reported Non Operating Income over the past 18 years, most recently at $195.5 million for Q1 2026.

  • For Q1 2026, Non Operating Income rose 43.71% year-over-year to $195.5 million; the TTM value through Mar 2026 reached $894.2 million, down 16.83%, while the annual FY2025 figure was $707.6 million, 0.79% up from the prior year.
  • Non Operating Income for Q1 2026 was $195.5 million at Gsk, down from $198.2 million in the prior quarter.
  • Over five years, Non Operating Income peaked at $446.9 million in Q4 2022 and troughed at -$211.5 million in Q1 2023.
  • A 5-year average of $218.9 million and a median of $198.2 million in 2025 define the central range for Non Operating Income.
  • Biggest five-year swings in Non Operating Income: skyrocketed 201.41% in 2022 and later plummeted 179.61% in 2023.
  • Year by year, Non Operating Income stood at $446.9 million in 2022, then fell by 9.46% to $404.6 million in 2023, then fell by 9.91% to $364.5 million in 2024, then plummeted by 45.63% to $198.2 million in 2025, then fell by 1.37% to $195.5 million in 2026.
  • Business Quant data shows Non Operating Income for GSK at $195.5 million in Q1 2026, $198.2 million in Q4 2025, and $136.0 million in Q1 2025.